20/20 Biolabs (NASDAQ:AIDX – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.12) EPS for the quarter, Zacks reports. The company had revenue of $0.38 million during the quarter.
20/20 Biolabs Stock Up 1.3%
Shares of AIDX stock opened at $0.19 on Wednesday. 20/20 Biolabs has a 52 week low of $0.18 and a 52 week high of $50.00. The firm’s 50-day simple moving average is $0.33 and its two-hundred day simple moving average is $0.94.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised 20/20 Biolabs from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, 20/20 Biolabs presently has an average rating of “Hold” and a consensus price target of $5.00.
Read Our Latest Analysis on 20/20 Biolabs
20/20 Biolabs Company Profile
20/20 BioLabs is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services. The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.
Further Reading
- Five stocks we like better than 20/20 Biolabs
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
